| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 50 | 2023 | 5444 | 3.800 |
Why?
|
| Gastrointestinal Microbiome | 12 | 2024 | 951 | 2.730 |
Why?
|
| Immunotherapy | 20 | 2024 | 3480 | 1.330 |
Why?
|
| Skin Neoplasms | 17 | 2023 | 4775 | 1.260 |
Why?
|
| Neoplasms | 22 | 2024 | 15695 | 1.250 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1377 | 1.150 |
Why?
|
| Diet | 2 | 2024 | 1476 | 0.930 |
Why?
|
| Obesity | 8 | 2023 | 2989 | 0.850 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2020 | 1313 | 0.820 |
Why?
|
| Body Mass Index | 5 | 2023 | 2289 | 0.770 |
Why?
|
| Exercise | 3 | 2023 | 1190 | 0.750 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2021 | 150 | 0.720 |
Why?
|
| Colitis | 4 | 2024 | 342 | 0.650 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2021 | 1069 | 0.580 |
Why?
|
| Qigong | 1 | 2016 | 12 | 0.560 |
Why?
|
| Tai Ji | 1 | 2016 | 14 | 0.560 |
Why?
|
| Waiting Lists | 3 | 2017 | 275 | 0.530 |
Why?
|
| Ipilimumab | 9 | 2023 | 749 | 0.510 |
Why?
|
| Interleukin-2 | 1 | 2018 | 851 | 0.500 |
Why?
|
| Molecular Targeted Therapy | 4 | 2022 | 2371 | 0.490 |
Why?
|
| Sleep Wake Disorders | 3 | 2016 | 357 | 0.470 |
Why?
|
| Fatigue | 4 | 2016 | 1265 | 0.470 |
Why?
|
| Diarrhea | 3 | 2021 | 690 | 0.450 |
Why?
|
| Humans | 81 | 2024 | 270303 | 0.440 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 2942 | 0.430 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 1558 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 16258 | 0.400 |
Why?
|
| Quality of Life | 7 | 2024 | 4702 | 0.390 |
Why?
|
| Prebiotics | 2 | 2023 | 35 | 0.390 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2023 | 1325 | 0.390 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3289 | 0.360 |
Why?
|
| Acupuncture Therapy | 3 | 2015 | 94 | 0.330 |
Why?
|
| CTLA-4 Antigen | 4 | 2023 | 665 | 0.320 |
Why?
|
| Probiotics | 2 | 2021 | 232 | 0.290 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 2980 | 0.290 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1007 | 0.280 |
Why?
|
| Hot Flashes | 3 | 2015 | 37 | 0.280 |
Why?
|
| Middle Aged | 29 | 2024 | 89347 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 3 | 2019 | 885 | 0.260 |
Why?
|
| Infliximab | 2 | 2024 | 140 | 0.250 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2023 | 109 | 0.250 |
Why?
|
| Cancer Survivors | 2 | 2024 | 721 | 0.240 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 5936 | 0.230 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 717 | 0.230 |
Why?
|
| Male | 29 | 2024 | 127343 | 0.230 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 3955 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2023 | 83 | 0.220 |
Why?
|
| Female | 34 | 2024 | 146977 | 0.220 |
Why?
|
| Survivors | 3 | 2017 | 1029 | 0.210 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 314 | 0.210 |
Why?
|
| Oximes | 3 | 2020 | 180 | 0.210 |
Why?
|
| Thinness | 1 | 2023 | 84 | 0.210 |
Why?
|
| Treatment Outcome | 14 | 2023 | 34144 | 0.210 |
Why?
|
| Animals | 16 | 2024 | 60962 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2022 | 4884 | 0.200 |
Why?
|
| Pyrimidinones | 3 | 2020 | 320 | 0.200 |
Why?
|
| Dermatitis | 1 | 2022 | 61 | 0.200 |
Why?
|
| Dietary Fiber | 1 | 2021 | 124 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 2 | 2019 | 258 | 0.190 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2021 | 17 | 0.190 |
Why?
|
| Pyridones | 3 | 2020 | 366 | 0.190 |
Why?
|
| Encephalitis | 1 | 2022 | 146 | 0.190 |
Why?
|
| Glutaminase | 1 | 2020 | 49 | 0.190 |
Why?
|
| Retrospective Studies | 13 | 2024 | 39457 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 257 | 0.180 |
Why?
|
| Feces | 2 | 2021 | 811 | 0.180 |
Why?
|
| Biological Products | 1 | 2024 | 311 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 383 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 290 | 0.180 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 893 | 0.170 |
Why?
|
| Risk Factors | 6 | 2023 | 18226 | 0.170 |
Why?
|
| Aged | 17 | 2024 | 72685 | 0.170 |
Why?
|
| Overweight | 1 | 2023 | 494 | 0.170 |
Why?
|
| Adult | 18 | 2022 | 80561 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2020 | 250 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 2730 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 357 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 418 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 152 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2020 | 7156 | 0.150 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 464 | 0.150 |
Why?
|
| Imidazoles | 3 | 2020 | 1029 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2021 | 358 | 0.150 |
Why?
|
| Protective Factors | 1 | 2018 | 110 | 0.150 |
Why?
|
| Antibodies | 2 | 2023 | 842 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 131 | 0.150 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 13879 | 0.150 |
Why?
|
| Leptin | 1 | 2019 | 307 | 0.150 |
Why?
|
| Microbiota | 1 | 2023 | 554 | 0.150 |
Why?
|
| B7-H1 Antigen | 3 | 2020 | 1057 | 0.150 |
Why?
|
| Neurofeedback | 1 | 2017 | 19 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2021 | 1057 | 0.140 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 142 | 0.140 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 16050 | 0.140 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 10623 | 0.140 |
Why?
|
| Mice | 11 | 2023 | 35298 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 92 | 0.140 |
Why?
|
| Inflammation | 2 | 2023 | 2570 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2018 | 256 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 597 | 0.140 |
Why?
|
| Taxoids | 2 | 2017 | 994 | 0.140 |
Why?
|
| Signal Transduction | 6 | 2023 | 12136 | 0.130 |
Why?
|
| Xerostomia | 2 | 2014 | 201 | 0.130 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 14497 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 522 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2018 | 332 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1534 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 3362 | 0.130 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 339 | 0.130 |
Why?
|
| Metformin | 1 | 2019 | 390 | 0.130 |
Why?
|
| Nausea | 2 | 2014 | 535 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 727 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 697 | 0.120 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 11816 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1118 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 547 | 0.120 |
Why?
|
| Dacarbazine | 1 | 2016 | 488 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 1890 | 0.120 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2016 | 199 | 0.120 |
Why?
|
| Estrogens | 1 | 2018 | 758 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 30718 | 0.120 |
Why?
|
| Arthralgia | 1 | 2014 | 97 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 560 | 0.110 |
Why?
|
| Age Factors | 2 | 2020 | 5489 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 465 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 390 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2019 | 1008 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 595 | 0.110 |
Why?
|
| Sleep | 1 | 2016 | 426 | 0.110 |
Why?
|
| Young Adult | 7 | 2021 | 22092 | 0.110 |
Why?
|
| Breathing Exercises | 1 | 2013 | 21 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 118 | 0.110 |
Why?
|
| Texas | 3 | 2024 | 6457 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 1323 | 0.100 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2022 | 4442 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 5292 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 7417 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 5105 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10254 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 873 | 0.100 |
Why?
|
| Time Factors | 4 | 2021 | 13246 | 0.100 |
Why?
|
| Prognosis | 8 | 2021 | 22228 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 2387 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 2122 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 999 | 0.090 |
Why?
|
| Electroacupuncture | 1 | 2010 | 33 | 0.090 |
Why?
|
| Ileus | 1 | 2010 | 31 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 3097 | 0.080 |
Why?
|
| Mutation | 3 | 2019 | 15578 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6269 | 0.080 |
Why?
|
| Colectomy | 1 | 2010 | 291 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2021 | 769 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 1470 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2022 | 9322 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2022 | 10092 | 0.070 |
Why?
|
| Adolescent | 5 | 2021 | 32284 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2023 | 4885 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2018 | 2914 | 0.070 |
Why?
|
| Pain Management | 1 | 2013 | 699 | 0.070 |
Why?
|
| Depression | 1 | 2017 | 1763 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 14851 | 0.070 |
Why?
|
| HIV Infections | 1 | 2018 | 2215 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 7157 | 0.060 |
Why?
|
| Incidence | 3 | 2021 | 5886 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1896 | 0.060 |
Why?
|
| United States | 5 | 2024 | 16312 | 0.060 |
Why?
|
| Biomarkers | 3 | 2021 | 5162 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 3619 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1625 | 0.060 |
Why?
|
| Antimetabolites | 1 | 2024 | 72 | 0.060 |
Why?
|
| New York | 1 | 2023 | 106 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1656 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2021 | 9471 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2013 | 2733 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2023 | 64 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 276 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5465 | 0.050 |
Why?
|
| Steroids | 1 | 2024 | 355 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4995 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 1429 | 0.050 |
Why?
|
| Disease Progression | 2 | 2023 | 6890 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 111 | 0.050 |
Why?
|
| Goals | 1 | 2022 | 192 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 245 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 161 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 9002 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4384 | 0.050 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 117 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 304 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 2210 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3930 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 229 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 377 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 155 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 387 | 0.040 |
Why?
|
| Oxadiazoles | 1 | 2019 | 60 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 784 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 282 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 512 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 558 | 0.040 |
Why?
|
| Phenotype | 2 | 2023 | 6392 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 608 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2019 | 102 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 259 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 764 | 0.040 |
Why?
|
| Medicare | 1 | 2024 | 925 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2023 | 13265 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 450 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 509 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 732 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 667 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 1131 | 0.040 |
Why?
|
| Survival Rate | 2 | 2022 | 12429 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2019 | 236 | 0.040 |
Why?
|
| Uveal Neoplasms | 1 | 2020 | 188 | 0.040 |
Why?
|
| Clostridium Infections | 1 | 2021 | 258 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2021 | 400 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 5239 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 747 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 7702 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 131 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 698 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 749 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 203 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 102 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2347 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2016 | 47 | 0.040 |
Why?
|
| Proteomics | 1 | 2023 | 1421 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1405 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 350 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 173 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 267 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1372 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1076 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 230 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 553 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 268 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 2027 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 689 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 286 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2019 | 888 | 0.030 |
Why?
|
| Aging | 1 | 2023 | 1563 | 0.030 |
Why?
|
| China | 1 | 2016 | 626 | 0.030 |
Why?
|
| Remission Induction | 1 | 2021 | 3620 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 689 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 2480 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 706 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 846 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 293 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 4520 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 219 | 0.030 |
Why?
|
| Piperidines | 1 | 2019 | 1067 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 6231 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 656 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 9064 | 0.030 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2013 | 39 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 117 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 905 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 1559 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 149 | 0.030 |
Why?
|
| Mitochondria | 1 | 2019 | 1306 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 167 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 1336 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 1706 | 0.030 |
Why?
|
| Rituximab | 1 | 2017 | 1551 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2013 | 172 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 620 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5509 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2013 | 384 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2013 | 389 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2019 | 4343 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 5114 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 2818 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 654 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2311 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 2018 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 708 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4230 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2837 | 0.020 |
Why?
|
| Defecation | 1 | 2010 | 59 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2016 | 1204 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 775 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3960 | 0.020 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 50 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 1459 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 4052 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 2010 | 94 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3252 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 3091 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 682 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2010 | 135 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 1432 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 720 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 1430 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6179 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1852 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 15176 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5913 | 0.010 |
Why?
|
| Pain | 1 | 2013 | 1689 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2010 | 640 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 7733 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2018 | 5816 | 0.010 |
Why?
|
| Child | 1 | 2016 | 30149 | 0.010 |
Why?
|